'Fall From Grace'
Who reported it (6)
- Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial The Business Journals · 9d ago
- Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study BioPharma Dive · 9d ago
- Ultragenyx's ASO fails in Angelman syndrome, triggering sell-off firstwordpharma.com · 9d ago
- Ultragenyx to slash costs after Angelman trial failure pharmaphorum · 9d ago
- Ultragenyx mulls fate of rare disease programme on Phase III flop Clinical Trials Arena · 9d ago
- 'Fall From Grace' Investor's Business Daily · 9d ago broke it first
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Related trends
Sam Altman: OpenAI won't go public this year as IPO now would come at an 'ill-advised moment'
OpenAI will not pursue an initial public offering in 2026, according to statements from Sam Altman.
More than 2 million sour candy bottles recalled over potentially deadly choking hazard
More than two million sour candy bottles face a nationwide recall due to a potentially deadly choking hazard.
Charity founder says he secretly gave FTX fraud figure Caroline Ellison a job
A 501c3 charity has secretly hired former Alameda Research CEO Caroline Ellison, testing the crypto sector's redemption culture.
Court Strikes Down Trump Order to Keep an Aging Coal-Burning Plant Running
A federal court has blocked an order to keep an aging Michigan coal plant running, delivering a blow to revival efforts.
Why Cheap Used Cars Are So Hard to Find
Affordable pre-owned vehicles are increasingly difficult to locate as buyers chase low-cost inventory.
IEA warns of ‘lost period’ in global oil demand
Global oil demand faces a lost period as escalating conflicts and supply gaps push refining systems to the limit.